Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naïve, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors

Patrick F. Smith, Gregory K. Robbins, Robert W. Shafer, Hulin Wu, Song Yu, Martin S. Hirsch, Thomas C. Merigan, Jeong Gun Park, Alan Forrest, Margaret A. Fischl, Gene D. Morse

Research output: Contribution to journalArticle

9 Scopus citations


Pharmacokinetic studies were conducted with human immunodeficiency virus-infected patients receiving efavirenz, nelfinavir, or both agents at weeks 4 and 32. Reductions of 25% and 45% were observed in the mean nelfinavir area under the concentration-time curve and minimum concentration of the drug in serum, and there was a 31% more rapid half-life for patients receiving both drugs compared to patients receiving nelfinavir alone. There were no significant differences in efavirenz pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)3558-3561
Number of pages4
JournalAntimicrobial agents and chemotherapy
Issue number8
StatePublished - Aug 1 2005


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this